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LETTER TO THE EDITOR
Interferon beta-1a as adjunctive treatment for
multifocal motor neuropathy: an open label trial
Dear Editor,
Infusions of intravenous immunoglobulins (IVIg)
are the only established therapy for patients with
multifocal motor neuropathy (MMN) (Umapathi et al.,
2009), but the effects are transient and the infusions
have to be repeated periodically (Van den Berg,
2007). As two pilot trials with interferon beta-1a
(INFβ-1a) as a monotherapy have suggested some
benefit (Martina et al., 1999; van den Berg-Vos et al.,
2000), we conducted a pilot trial with INFβ-1a as
adjunctive therapy to assess the effect on the
IVIg dose requirement in patients with MMN who
were responsive to IVIg but required chronic IVIg
therapy.
We recruited three MMN patients who had
been treated with IVIg on an average of 6 years
with IVIg therapy at one infusion every 2–6 weeks
(Kuntzer et al., 2007). Prior attempts to wean the
patients from IVIg by combining immunosuppressant
agents (mofetil mycophenolate and intravenous
cyclophosphamide) had failed. This study was a
prospective, unblinded, uncontrolled, 6-month pilot
study. INFβ-1a (Rebif®, sponsored by MerckSerono
Inc., Switzerland) was administered at a 44 μg
dose three times a week subcutaneously during
6 months whereas IVIg therapy was maintained.
The patients could prolong INFβ-1a treatment by
3 months. Total IVIg dose was recorded in the
12 months prior, during, and 6 months after the
introduction of INFβ-1a. We hypothesized that the
addition of INFβ-1a would result in a reduction of
IVIg dose or in prolonged intervals between IVIg.
Secondary endpoints included: improvement of upper
extremity INCAT score; improved strength in 15
muscles according to the Neurological Disability Scale;
reduction of treatment costs; and improved quality of
life by using the SF-36 questionnaire. Nerve conduction
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studies were obtained at baseline and at the end of
the study.
Primary and secondary endpoints before, during,
and after the introduction of INFβ-1a are reported
in Table 1. The interval between each infusion was
lengthened by 2 weeks in Patients 1 and 2 and
was unchanged in Patient 3 (Table 1). Patients 1 and
2 experienced a more rapid recovery and a slower
relapse after each IVIg therapy when combined with
INFβ-1a and opted to prolong their INFβ-1a by 3
months. Only Patient 2 maintained a prolonged interval
of IVIg infusions after discontinuing INFβ-1a. We did
not observe changes in the medical research council
(MRC) scale, the inflammatory neuropathy cause and
treatment (INCAT) score, the quality of life, treatment
costs, or electrophysiological parameters.
A combination therapy should hinder the progres-
sion of MMN, allow reduction of IVIg doses, or allow
lengthening of IVIg infusion intervals (Umapathi et al.,
2009). Although 2 of our 3 patients increased their
infusion intervals while on INFβ-1a, none elected to
continue treatment beyond the study period due to
mild side effects and modest benefits. Thus, our lim-
ited experience would not support larger trials. As we
studied only 3 patients, we also wonder about the
experience of others treated with INFβ-1a but not in
the literature.
Sincerely,
Alexander J. Radziwill,
Stephan A. Botez,
Jan Novy, and
Thierry Kuntzer
Nerve-Muscle Unit, Neurology Service,
Centre Hospitalier Universitaire Vaudois (CHUV) and
University of Lausanne, Lausanne,
Switzerland
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Table 1. Primary and secondary endpoints before and after INFβ-1a treatment.
Interval
Disease Nerves between IVIg Mean IVIg
Patients, sex, duration; type involved infusions dose per MRC sum INCAT SF-36
age (years) of weakness with CB Anti-GM1 Ab (weeks) month (g) score (points) (points) (points)
Before; during; after INFβ-1a Before; after INFβ-1a
1, female, 66 4 years;
↓ left
handgrip
and arm
flexion
Left musculo-
cutaneous
and radial
Positive 6; 8; 6 78; 58.5; 78 5; 6 2; 2 55; 55
2, male, 35 9 years;
↓ handgrip
bilaterally
Bilateral ulnar
and median
Negative 5; 7; 6 138.6; 99; 115.5 14; 11 3; 3 92; 93
3, male, 47 5 years;
↓ right
handgrip
Right ulnar
and median
Negative 2; 2; 2 Always 86.6 3; 3 3; 3 83; 87
INFβ-1a, interferon beta-1a; CB, conduction block; Ab, antibodies
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